TY - JOUR
T1 - Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy
AU - Pappalardo, Federico
AU - Franco, A.
AU - Crescenzi, G. G.
AU - Poli, A.
AU - Zangrillo, A.
AU - Koster, A.
PY - 2007
Y1 - 2007
N2 - Heparin-induced IgE-mediated hypersensitivity and anaphylactoid reactions, although rare, can pose a serious clinical problem for patients requiring cardiopulmonary bypass (CPB). Bivalirudin is a bivalent reversible direct thrombin inhibitor, with a half-life of 25 min, eliminated mostly by proteolytic cleavage. There are some reports on the use of bivalirudin for cardiac surgery, particularly for heparin-induced thrombocytopenia (HIT), but none on cases of heparin allergy. We report a case of heparin allergy successfully managed for CPB with bivalirudin anticoagulation.
AB - Heparin-induced IgE-mediated hypersensitivity and anaphylactoid reactions, although rare, can pose a serious clinical problem for patients requiring cardiopulmonary bypass (CPB). Bivalirudin is a bivalent reversible direct thrombin inhibitor, with a half-life of 25 min, eliminated mostly by proteolytic cleavage. There are some reports on the use of bivalirudin for cardiac surgery, particularly for heparin-induced thrombocytopenia (HIT), but none on cases of heparin allergy. We report a case of heparin allergy successfully managed for CPB with bivalirudin anticoagulation.
UR - http://www.scopus.com/inward/record.url?scp=34347379536&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347379536&partnerID=8YFLogxK
U2 - 10.1177/0267659106076004
DO - 10.1177/0267659106076004
M3 - Article
C2 - 17633138
AN - SCOPUS:34347379536
VL - 22
SP - 67
EP - 69
JO - Perfusion
JF - Perfusion
SN - 0267-6591
IS - 1
ER -